Gene Therapy Analytical Development 2023

Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy, robust and detailed analytics are the cornerstone of gene therapy development. As regulators scrutinize products more closely, accurately characterizing gene therapy products and standing behind safety and efficacy is crucial to drug developers bringing gene therapies into and through the clinic.

In this context, the 5th Annual Gene Therapy Analytical Development is returning in 2023, uniting 400+ analytical experts to explore how the latest analytical methods are being developed and applied to guarantee the quality, consistency, safety, and efficacy of gene therapy products.

Join biopharma colleagues specializing in bioassays, molecular biology, physicochemical properties, quality, process development and regulation across 4 days of niche, expert presentations, and dedicated networking opportunities. This is your must-attend meeting to collaborate ideas, success and challenges to capitalize on the technological advances in analytical development to reach the ultimate goal of bringing safer, efficacious therapies to patients more quickly and effectively.



URLs:
Website: https://go.evvnt.com/1860488-0?pid=2874
Brochure: https://go.evvnt.com/1860488-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Drug Developer Pricing - Full Access Pass (Conference + Pre Conference Workshop Day AND Post Conference Day): USD 5195.00,
Drug Developer Pricing - Conference + Pre Conference Workshop Day OR Post Conference Day: USD 4197.00,
Drug Developer Pricing - Conference Only: USD 3199.00,
Solution Provider Pricing - Full Access Pass (Conference + Pre Conference Workshop Day AND Post Conference Day): USD 6195.00,
Solution Provider Pricing - Conference + Pre Conference Workshop Day OR Post Conference Day: USD 5197.00,
Solution Provider Pricing - Conference Only: USD 4199.00

Speakers: Adam Washburn, Director, Research and Development, Eli Lilly, Akshata Ijantkar, Senior Principal Scientist and CMC Team Lead, Gene and Cell Therapy Programs, Bristol Myers Squibb, Allison Schorzman, Scientist II, BridgeBio Gene Therapy, Alyssa Batista, Senior Research Associate, Astellas Gene Therapies, Amod Joshi, Scientist II, Analytical Development, BridgeBio Gene Therapy, Angela Whatley, Regulatory Consultant and Ex-FDA Biologist, Independent, Anindya Dasgupta, Director, GMP, Expression Therapeutics LLC, Arun Rooj, Associate Director, Gene Therapy Analytical Development, Sarepta Therapeutics, Bartlomiej Blus, Associate Director, Group Leader, Biomarin Pharmaceuticals, Binod Pandey, Senior Scientist, Novartis Gene Therapies, Brian Mosley, Scientist II, Analytical Science and Technology Lead, BridgeBio Gene Therapy, Cindy Chen, Senior Scientist, AAV Process Development, Intellia Therapeutics, Craig Jerome, Bio-Assay Associate, Beacon Therapeutics, David Diguiseppi, Senior Scientist II, Biophysical Analytical Development, Technical Operations, Passage Bio, David Dobnik, Senior Research Associate, National Institute of Biology, David Schwalb, Director Analytical Development, Cell and Gene Therapies, Pacira Biosciences, Dawn Henke, Senior Scientific Program Manager, Standards Coordinating Body, Dillon Kavanagh, Senior Research Associate I, Voyager Therapeutics, Emily Menesale, Scientist II, Analytical Development, Ultragenyx Pharmaceuticals, Eric Yearley, Associate Director, Analytical Development, BridgeBio Gene Therapy, Franco Puleo, Scientist II, Technical Development, Gene Therapy, Biogen, George Bou-Assaf, Associate Director, Analytical and Biophysical Development, Biogen, Haiqing Yu, Senior Scientist, Bioassays and Molecular Biology, Sanofi, Hao Liu, Postdoctoral Researcher, Horae Gene Therapy Center, UMass Chan Medical School, Ilya Shestopalov, Vice President - Analytical Development and Product Lead, bluebird bio, Jiwen Zhang, Vice President, Global Regulatory Affairs, PharmaEssentia, Joshua Zibit, Head of Technical Development, Astellas Gene Therapies, Justin DeFrancisco, Senior Scientist, Molecular Assay Lead, Intergalactic Therapeutics, Lyndi Rice, Senior Director and Head Of Gene Therapy Analytical Technology, BioMarin Pharmaceutical, Margaret Butko, Associate Director - Protein and Analytical Characterization, Adverum Biotechnologies, Marina Feschenko, Senior Director, Analytical Development, Cell and Gene Therapy, Vertex Pharmaceuticals, Matteo Placidi, Associate Director, Analytical Science, Voyager Therapeutics, Matthew Lotti, Senior Research Associate II, Ultragenyx Pharmaceuticals, Matthew McLaughlin, Associate Scientist, Assay Development, Abeona Therapeutics, Michael Kahse, Senior Scientist - Viral Vector Protein Analytics, CSL Behring, Michelle McCarty, Lead Research Associate, Gene Therapy Process Development, Sarepta Therapeutics, Michelle Sawyer, Bio-Assay Associate II, Beacon Therapeutics, Minjia Wang, Analytical Scientist, Prime Medicine, Niomi Peckham, Director, Pipeline Development Global Biologics, United States Pharmacopeia, Nisarg Patel, High Throughput Analytics and Operations Lead, Spark Therapeutics, Pete Clarner, Scientist I, Gene Therapy Accelerator Unit, Biogen, Pocheng Liu, Executive Director - Chemistry Manufacturing and Controls Analytical and Formulation Development Analytical and Formulation Develo, Locana, Inc., Prasad Kesanakurti, NGS Scientist, Sanofi, Richard Wu, PhD Bioengineering Student, MIT, Rie Takino, Researcher, Analytical and Quality Evaluation Research Laboratories, Daiichi Sankyo, Ronald Toth, Senior Scientist, Characterization, Sanofi, Ross Thurston, Scientist II, Bioassays Team Leader, AskBio, Sahar Tavakoli, Associate Teaching Professor and Director of Cell and Gene Therapy Programs, Northeastern University, Sambit Kar Analytical, Development Lead, Structural Characterization, Spark Therapeutics, Sarah Wassmer, Quality , Cells, Gene Therapies and Radiopharmaceuticals Division Evaluator, Health Canada, Scott Burger, Principal, Advanced Cell and Gene Therapy, Sheetal Bhan, Senior Scientist, Bioassay and Molecular Analytical Development, Genomic Medicines Unit, Sanofi, Shilin Cheung, Senior Research Scientist, Phenomenex, Shilpa Suravajhala, Senior Scientist, Analytical Development, bluebird bio, Suman Jangid, Associate Director - Global Regulatory, Novel Gene Therapy, Chemistry, Manufacturing and Control, Omega Therapeutics, Inc., Ting He, Senior Scientist, AAV Pharmaceutical Development, Ultragenyx Pharmaceuticals, Vinay Kondeti, Senior Scientist, BridgeBio Gene Therapy, Wei Cao, Analytical Program Lead, Spark Therapeutics, Yixin Li, Principal Scientist, Adverum Biotechnologies, Zhenhong Li, Executive Director, Analytical Development and Quality Control, Passage Bio